文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

神经内分泌肿瘤诊断前的既往症状和医疗保健利用:一项 SEER-Medicare 数据库研究。

Pre-existing Symptoms and Healthcare Utilization Prior to Diagnosis of Neuroendocrine Tumors: A SEER-Medicare Database Study.

机构信息

Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, USA.

Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, USA.

出版信息

Sci Rep. 2018 Nov 15;8(1):16863. doi: 10.1038/s41598-018-35340-4.


DOI:10.1038/s41598-018-35340-4
PMID:30442902
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6238007/
Abstract

The incidence and prevalence of neuroendocrine tumors (NETs) are continually increasing. While it is known that NET symptoms often predate diagnosis, their prevalence and impact on resource utilization and costs are largely unknown. We identified 9,319 elderly patients diagnosed with NETs between 1/2003 and 12/2011 from the Surveillance, Epidemiology and End Results (SEER)-Medicare. We examined the patients' conditions potentially associated with NET, resource utilization and costs during the year before diagnosis. We found that NET patients were more likely to have diagnoses of hypertension (63.8% vs. 53.3%), abdominal pain (22.2% vs. 7.6%), heart failure (11.7% vs. 8.0%), diarrhea (5.8% vs. 1.8%), peripheral edema (5.4% vs. 3.8%) and irritable bowel syndrome (1.2% vs. 0.5%) compared to the non-cancer control group. They also had much higher resource utilization including number of outpatient visits (mean: 22.1 vs. 17.2), percentage with ER visits (20.9% vs. 11.6%), and hospitalizations (28.4% vs. 17.0%). Similarly, NET patients incurred significantly higher total (mean: $14602 vs. $9464), outpatient (mean: $5987 vs. $4253), and inpatient costs (mean: $8615 vs. $5211). This first population-based study on the pre-diagnosis symptoms and healthcare utilization found that NET patients were more likely to have certain conditions and incur higher resource utilizations and costs.

摘要

神经内分泌肿瘤(NET)的发病率和患病率持续上升。虽然已知 NET 症状通常先于诊断出现,但它们的患病率及其对资源利用和成本的影响在很大程度上尚不清楚。我们从监测、流行病学和最终结果(SEER)-医疗保险数据库中确定了 9319 名在 2003 年 1 月至 2011 年 12 月期间被诊断为 NET 的老年患者。我们研究了患者在诊断前一年可能与 NET 相关的疾病、资源利用和成本情况。我们发现,NET 患者更有可能被诊断出患有高血压(63.8%比 53.3%)、腹痛(22.2%比 7.6%)、心力衰竭(11.7%比 8.0%)、腹泻(5.8%比 1.8%)、外周水肿(5.4%比 3.8%)和肠易激综合征(1.2%比 0.5%)。与非癌症对照组相比,他们的资源利用也更高,包括门诊就诊次数(平均:22.1 比 17.2)、急诊就诊比例(20.9%比 11.6%)和住院率(28.4%比 17.0%)。同样,NET 患者的总费用(平均:$14602 比 $9464)、门诊费用(平均:$5987 比 $4253)和住院费用(平均:$8615 比 $5211)也显著更高。这是第一项关于 NET 患者诊断前症状和医疗保健利用情况的基于人群的研究,发现 NET 患者更有可能患有某些疾病,并产生更高的资源利用和成本。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc23/6238007/3cb252afca2c/41598_2018_35340_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc23/6238007/3cb252afca2c/41598_2018_35340_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc23/6238007/3cb252afca2c/41598_2018_35340_Fig1_HTML.jpg

相似文献

[1]
Pre-existing Symptoms and Healthcare Utilization Prior to Diagnosis of Neuroendocrine Tumors: A SEER-Medicare Database Study.

Sci Rep. 2018-11-15

[2]
Healthcare utilization and costs associated with COPD among SEER-Medicare beneficiaries with NSCLC.

J Med Econ. 2018-9

[3]
Carcinoid Syndrome and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients.

Oncologist. 2017-6-22

[4]
Costs of Cancer Care for Elderly Patients with Neuroendocrine Tumors.

Pharmacoeconomics. 2018-8

[5]
First-line systemic treatment adherence, healthcare resource utilization, and costs in patients with gastrointestinal neuroendocrine tumors (GI NETs) in the USA.

J Med Econ. 2018-8

[6]
Treatment adherence, healthcare resource utilization, and costs in patients with lung neuroendocrine tumors (lung NETs) in the USA.

Curr Med Res Opin. 2018-8-10

[7]
Resource Use in the Last Year of Life Among Patients Who Died With Versus of Prostate Cancer.

Clin Genitourin Cancer. 2016-2

[8]
Healthcare Utilization and Costs During the Initial Phase of Care Among Elderly Women With Breast Cancer.

J Natl Compr Canc Netw. 2017-11

[9]
Neuroendocrine tumor epidemiology: contrasting Norway and North America.

Cancer. 2008-11-15

[10]
Direct economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-Medicare linked database.

Appl Health Econ Health Policy. 2009

引用本文的文献

[1]
Patterns of emergency department visits before diagnosis with digestive neuroendocrine neoplasms.

Int J Colorectal Dis. 2023-5-31

[2]
Update on Prevalence of Pain in Patients with Cancer 2022: A Systematic Literature Review and Meta-Analysis.

Cancers (Basel). 2023-1-18

[3]
Role of Combined Ga DOTA-Peptides and F FDG PET/CT in the Evaluation of Gastroenteropancreatic Neuroendocrine Neoplasms.

Diagnostics (Basel). 2022-1-22

[4]
The synergistic effects of TGF-β1 and RUNX2 on enamel mineralization through regulating ODAPH expression during the maturation stage.

J Mol Histol. 2022-4

[5]
Early Identification of Residual Disease After Neuroendocrine Tumor Resection Using a Liquid Biopsy Multigenomic mRNA Signature (NETest).

Ann Surg Oncol. 2021-11

[6]
Evaluating cost-effectiveness in the management of neuroendocrine neoplasms.

Rev Endocr Metab Disord. 2021-9

[7]
Racial/Ethnic Disparities and Survival Characteristics in Non-Pancreatic Gastrointestinal Tract Neuroendocrine Tumors.

Cancers (Basel). 2020-10-15

[8]
Symptoms in Blastomycosis, Coccidioidomycosis, and Histoplasmosis Versus Other Respiratory Illnesses in Commercially Insured Adult Outpatients-United States, 2016-2017.

Clin Infect Dis. 2021-12-6

[9]
The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors.

Adv Med Sci. 2020-3

本文引用的文献

[1]
Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs.

J Glob Oncol. 2016-6-8

[2]
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.

JAMA Oncol. 2017-10-1

[3]
Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study.

Lancet Oncol. 2017-4

[4]
Pathways to Lung Cancer Diagnosis: A Qualitative Study of Patients and General Practitioners about Diagnostic and Pretreatment Intervals.

Ann Am Thorac Soc. 2017-5

[5]
Understanding pathways to breast cancer diagnosis among women in the Western Cape Province, South Africa: a qualitative study.

BMJ Open. 2016-1-4

[6]
Symptom appraisal and healthcare-seeking for symptoms suggestive of colorectal cancer: a qualitative study.

BMJ Open. 2015-10-9

[7]
Comparison of World Health Organization 2000/2004 and World Health Organization 2010 classifications for gastrointestinal and pancreatic neuroendocrine tumors.

Ann Diagn Pathol. 2015-4

[8]
Consensus guidelines for the management and treatment of neuroendocrine tumors.

Pancreas. 2013-5

[9]
Clinical aspects, diagnostic challenges and management of patients with neuroendocrine tumors (NETs).

Onkologie. 2011

[10]
NANETS consensus guidelines for the diagnosis of neuroendocrine tumor.

Pancreas. 2010-8

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索